The developer of an innovative, first-in-class, noninvasive device for the treatment of spasticity in multiple sclerosis (MS) and other conditions has won the 2019 CCI France International Trophy for Innovation.
PathMaker Neurosystems was selected from a list of eight finalist companies, which were distinguished among 150 nominees from 40 countries and across all technology sectors, for its development of MyoRegulator PM-2200, a direct-nerve stimulation treatment.
This prize aims to recognize companies that produce breakthrough technology that encourages economic ties between France and French companies with the rest of the world. Award criteria include significant investments in research and development, use of new technologies, high growth potential, originality, and revolutionary projects and ideas.
“We are incredibly honored to have been named the recipient of this award, and would like to express our sincere appreciation to the CCI France International committee for this kind recognition of PathMaker’s progress in developing MyoRegulator, our first-in-class, non-invasive device for the treatment of patients suffering from spasticity,” Nader Yaghoubi, MD, PhD, president and CEO of PathMaker, said in a press release.
“Building on the momentum we received last year from the French-American Business (FAB) Award for Startup of the Year from FACCNE [French-American Chamber of Commerce of New England], the 2019 CCI France International Trophy for Innovation is a testament to the work done by our team and collaborators in bringing this breakthrough device to patients,” he added.
Boston-based PathMaker, which has offices in Paris, is a clinical-stage bioelectronic drug company created to commercialize advances in the development of noninvasive systems for treating neuromotor disorders, including MS and cerebral palsy. In addition to spasticity, Pathmakers’ new device was designed to treat muscle weakness and paralysis.
The company’s first product, MyoRegulator is based on PathMaker’s proprietary DoubleStim technology, and uses electrical stimulus to regulate nerve cell activity. It suppresses the overreaction that causes spasticity. The technology uses two pairs of disposable skin-surface electrodes to deliver simultaneous stimulation to two sites along the central nervous system (neural axis) — at the spinal outflow and at the peripheral nerve controlling the affected muscle.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?